India

Population 2018: 1 353 million

### Tuberculosis profile

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>2 690 (1 840–3 700)</td>
<td>199 (136–273)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>92 (63–126)</td>
<td>6.8 (4.6–9.3)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceºº</td>
<td>130 (77–198)</td>
<td>9.6 (5.7–15)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>440 (410–470)</td>
<td>32 (30–35)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>8.7 (5.7–15)</td>
<td>0.72 (0.42–1.1)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**
- New cases: 2.8% (2.3–3.5)
- Previously treated cases: 14% (14–14)

**TB case notifications, 2018**
- Total new and relapse: 1 994 000
  - % tested with rapid diagnostics at time of diagnosis: 50%
  - % with known HIV status: 72%
  - % pulmonary: 82%
  - % bacteriologically confirmedººº: 57%
  - % children aged 0-14 years: 6%
  - % women: 34%
  - % men: 60%
- Total cases notified: 2 155 894

**Universal health coverage and social protection**
- TB treatment coverage (notified/estimated incidence), 2018: 74% (54–110)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 17% (12–24)
- TB/HIV care in new and relapse TB patients, 2018
  - Number (%) on antiretroviral therapy: 44 080 (90%)

***Drug-resistant TB care, 2018***
% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
- New cases: 46%
- Previously treated cases: 91%

**Laboratory-confirmed cases**
- MDR/RR-TB: 58 347, XDR-TB: 3 400
- Patients started on treatment**
  - MDR/RR-TB: 46 569, XDR-TB: 2 724

**MDR/RR-TB cases tested for resistance to second-line drugs**: 38 236

**Treatment success rate and cohort size**
- New and relapse cases registered in 2017: 81% (1 568 392)
- Previously treated cases, excluding relapse, registered in 2017: 96% (146 982)
- HIV-positive TB cases registered in 2017: 71% (31 213)
- MDR/RR-TB cases started on second-line treatment in 2016: 48% (33 197)
- XDR-TB cases started on second-line treatment in 2016: 30% (2 464)

**TB preventive treatment, 2018**
% of HIV-positive people (newly enrolled in care) on preventive treatment: 17%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 26% (24–28)

**TB financing, 2019**
- National TB budget (US$ millions): 583
- Funding source: 77% domestic, 23% international, 0% unfunded

---

*Ranges represent uncertainty intervals
º MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ºº MDR is TB resistant to isoniazid only
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-03-14
Data: www.who.int/tb/data